Patent intelligence · US
US 11767367
Monoclonal antibody neo-201 for the treatment of human carcinomas
Monoclonal antibody neo-201 for the treatment of human carcinomas
Patent details — US 11767367
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 26, 2023
- Expiration
- Sep 21, 2043
- Applicant
- PRECISION BIOLOGICS, INC.
- Claims
- 19
- CPC classes
- A61K, A61K2039/505, A61K38/05, A61K38/1725
Quick answer
US 11767367 (Monoclonal antibody neo-201 for the treatment of human carcinomas) is held by PRECISION BIOLOGICS, INC.. Status: granted. Granted Sep 26, 2023. Expires Sep 21, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PRECISION BIOLOGICS, INC.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K2039/505, A61K38/05, A61K38/1725, A61K38/20, A61K38/2013
More from PRECISION BIOLOGICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12419920
Bifidobacterium longum NCIMB 41676
granted -
US 12410418
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
granted -
US 12351839
Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
granted -
US 12344676
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
granted -
US 12336835
Neuromodulation to target glucose transporter and/or incretin pathways
granted -
US 12232492
Disinfection of bacteriophages products using supercritical carbon dioxide
granted -
US 12233135
Therapeutic constructs for treating cancer
granted -
US 12180463
Lactobacillus reuteri
granted
Frequently asked questions
What is US patent 11767367?
US 11767367 (Monoclonal antibody neo-201 for the treatment of human carcinomas) is held by PRECISION BIOLOGICS, INC.. Status: granted. Granted Sep 26, 2023. Expires Sep 21, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11767367?
PRECISION BIOLOGICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 158 pharmaceutical patents for this assignee.
When does US 11767367 expire?
Our index shows an expiration date of Sep 21, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.